GlassScriptPhysician profile
Chang Xu
NPI 1619112075
$10,915.15
in general payments reported to CMS, 2019-2025
22 companies · $4,901 in 2025
The $4,901 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $1,920 · 2021: $1,200 · 2022: $304 · 2023: $209 · 2024: $1,345 · 2025: $4,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,874 · Food and Beverage: $2,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,873.67 |
| Food and Beverage | $2,581.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $3,987.58 | 2025 | |
| Travere Therapeutics, INC. | $2,939.66 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $2,173.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $212.88 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $207.25 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $194.06 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $177.76 | 2022-2023 | |
| Glaxosmithkline, LLC. | $150.12 | 2023-2025 | |
| Daiichi Sankyo INC. | $124.15 | 2023 | Injectafer |
| Vifor Pharma, INC. | $122.48 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $114.52 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $108.15 | 2019 | |
| Horizon Therapeutics Plc | $92.89 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $86.28 | 2020 | |
| Genzyme Corporation | $68.37 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $54.56 | 2019-2020 | |
| Akebia Therapeutics INC | $41.22 | 2020 | |
| Shire North American Group INC | $29.77 | 2019 | |
| Fresenius USA Marketing, INC. | $18.38 | 2019 | |
| Dentsply Sirona INC | $11.17 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chang Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.